Pfizer Inc. (NYSE:PFE) shares are reacting to a mix of clinical pipeline news, dividend and earnings updates, analyst ratings and legal developments. Here’s what’s moving the stock:
Positive Sentiment:
Zacks highlights PFE’s strong earnings surprise history and expects another beat in its next report.
Will Pfizer (PFE) Beat Estimates Again?
Positive Sentiment:
Pfizer and Astellas report positive Phase 3 EMBARK trial results for XTANDI plus leuprolide in non-metastatic hormone-sensitive prostate cancer, showing improved overall survival.
Pfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study
Positive Sentiment:
New study data suggest abrocitinib could be a game-changer for atopic dermatitis patients.
Pfizer’s New Study on Abrocitinib: A Potential Game-Changer for Atopic Dermatitis
Positive Sentiment:
An S&P 500 dividend roundup highlights PFE’s 6.7% indicated yield, with another small increase likely by year-end.
“Nobody Ever Went Broke Taking a Profit” – Grab The Highest-Yielding S&P 500 Stocks Right Now
Positive Sentiment:
Shares climbed 1.7% on optimism around valuation and the strength of Pfizer’s pipeline.
Pfizer (NYSE:PFE) Trading Up 1.7% – Should You Buy?
Neutral Sentiment:
Cantor Fitzgerald trims its FY2025 EPS forecast slightly to $3.09 but keeps a Neutral rating and $24 price target.
Pfizer FY2025 EPS Forecast Decreased by Cantor Fitzgerald
Neutral Sentiment:
Bernstein reaffirms a Hold rating on PFE, citing steady cash flows and a deep drug pipeline.
Bernstein Sticks to Its Hold Rating for Pfizer (PFE)
Negative Sentiment:
The stock dipped 1.3% amid profit-taking and sell-side caution over valuation.
Pfizer (NYSE:PFE) Stock Price Down 1.3% – Here's Why
Negative Sentiment:
Pfizer and BioNTech appeal a UK patent ruling favoring Moderna, extending legal uncertainty around COVID-19 vaccine royalties.
Pfizer, BioNTech ask UK court to overturn Moderna's COVID vaccine patent win
Posted 1+ days ago
AI Generated. May Contain Errors.